Intuitive Surgical (ISRG) Drops -15% in 30 Days After Q2 Earnings
Key Takeaways
- Intuitive Surgical shares dropped approximately 15% over the past 30 days, accelerating sharply after the company's second-quarter 2026 earnings report released on July 16.
- Q2 revenue rose 19% year-over-year to $2.89 billion and adjusted EPS of $2.80 beat Wall Street estimates, yet investors focused on unchanged full-year procedure growth guidance.
- Management reaffirmed 2026 da Vinci procedure growth of 13.5%–15.5% and indicated it expects results closer to the midpoint, implying slower growth in the second half of the year.
- ACA premium subsidy uncertainty and moderating U.S. elective procedure volumes contributed to a more cautious near-term outlook, triggering a wave of analyst price target cuts.
- The stock hit a 52-week low and broke below its 200-week moving average, though the consensus analyst rating remains "Moderate Buy" with an average price target near $523.
Intuitive Surgical (ISRG) Company Overview and Market Position
Intuitive Surgical, headquartered in Sunnyvale, California, is the global leader in robotic-assisted minimally invasive surgery. The company's flagship da Vinci surgical systems enable surgeons to perform complex procedures with enhanced precision, smaller incisions, and improved patient recovery times. As of June 30, 2026, the installed base exceeded 11,700 da Vinci systems worldwide, complemented by the Ion endoluminal platform for minimally invasive lung biopsies, which reached 1,096 systems.
Intuitive's business model is built around a razor-and-blade framework: system placements generate a long tail of recurring revenue from instruments, accessories, and services. Recurring revenue accounted for roughly 85% of total quarterly sales in Q2 2026, underscoring the predictability of the company's cash flows. With first-mover scale, high switching costs for hospitals, and a deeply trained surgeon ecosystem, Intuitive maintains a formidable competitive moat despite emerging competition from JNJ, MDT, and SYK. Investors closely follow ISRG as a bellwether for medtech innovation and surgical robotics adoption trends. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Intuitive Surgical (ISRG) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 calendar days, ISRG shares fell from a closing price of $406.78 on June 18, 2026, to $345.42 on July 17, 2026 — a decline of roughly 15%. The bulk of that loss occurred on a single day: July 17, when the stock plunged 14.1% following the Q2 earnings release, marking its worst single-session performance in years and hitting a 52-week low of $344.55.
Looking at the broader quarterly picture, the stock has been under sustained pressure. ISRG entered the second quarter trading above $440 and has now shed approximately 22% over the trailing three months. From its 52-week high of $603.88, the stock has declined roughly 43% year-to-date, reflecting a prolonged compression in valuation multiples as growth expectations recalibrated amid softening procedure volume trends and macro uncertainty in the healthcare sector.
What Drove ISRG Stock Price in the Last 30 Days
The primary catalyst behind the 30-day decline was Intuitive Surgical's Q2 2026 earnings report, released after markets closed on July 16. While headline numbers exceeded expectations — revenue of $2.89 billion versus the $2.82 billion consensus and adjusted EPS of $2.80 versus the $2.50 estimate — management's forward guidance disappointed a market accustomed to beat-and-raise quarters.
The company left its full-year da Vinci procedure growth forecast unchanged at 13.5% to 15.5% and narrowed expectations to the midpoint of approximately 14.5%. To investors, this signaled that the strong 15% da Vinci procedure growth posted in Q2 would not carry into the second half of the year. Adding to the unease, U.S. da Vinci procedure growth decelerated to 12% in Q2 from 14% in Q1, with CEO Dave Rosa acknowledging that changes in patient coverage and Affordable Care Act premium dynamics were affecting when patients seek elective care.
The earnings miss on guidance triggered a cascade of analyst price target reductions. Citi cut its target from $590 to $500 and removed ISRG from its "Upside 90-Day Catalyst Watch." JPMorgan lowered its target from $550 to $450, Mizuho dropped from $500 to $400, and Bernstein slashed from $750 to $685. Leerink Partners, BTIG, and Baird all trimmed their targets as well, though nearly all maintained Buy or Outperform ratings.
The sell-off was amplified by a risk-off shift that had already begun earlier in the week. On July 14, HCA Healthcare trimmed its full-year outlook, signaling weaker surgical volumes industry-wide and sending medtech stocks broadly lower. ISRG, which had already retreated roughly 32% from its 2025 peak, entered the earnings event with fragile sentiment, and the unchanged guidance proved to be the tipping point.
What Drove ISRG Stock Performance Over the Last Quarter
The quarterly decline reflects more than a single earnings disappointment. Throughout 2026, Intuitive Surgical has grappled with a shifting narrative around growth sustainability. The company's valuation — which at its peak traded near 60 times forward earnings — priced in an expectation of sustained high-teens procedure growth. As that growth moderated into the mid-teens range, the premium multiple contracted. Broader sector headwinds compounded the pressure: hospitals faced ongoing staffing constraints, changes to ACA exchange subsidies introduced uncertainty around patient volumes in the U.S., and geopolitical tensions in China — a key growth market for Intuitive — added another layer of risk. Competition from emerging robotic platforms by JNJ, MDT, and SYK also began to feature more prominently in investor debates, even if Intuitive's installed-base advantage remains substantial. The cumulative effect was a steady, grinding decline that the Q2 guidance reaffirmation accelerated into a sharp correction.
ISRG Stock Forecast Drivers: What Investors Should Watch Next
Several factors will determine whether ISRG can stabilize and recover from its current sell-off. The most immediate focus will be on third-quarter procedure volume data and any updates to the full-year outlook. If U.S. procedure growth stabilizes or re-accelerates as ACA-related uncertainties resolve, sentiment could improve meaningfully. Conversely, any further deceleration would likely renew downward pressure. Beyond procedures, investors should monitor the uptake of da Vinci 5 systems — 246 were placed in Q2, up from 180 a year earlier — as a gauge of next-generation platform adoption. The company's growing Ion installed base and digital solutions portfolio represent longer-term growth vectors. Macro factors, including interest rate policy, hospital capital spending trends, and regulatory developments around healthcare coverage, will also play a critical role. With analysts maintaining a consensus Moderate Buy rating and an average price target of approximately $523 — implying roughly 50% upside from current levels — the debate centers on whether the growth deceleration is temporary or structural. From what I see, I’m watching procedure volumes closely here.
Trending AI Robots
In navigating volatile market environments like the one currently affecting Intuitive Surgical, I often turn to data-driven tools for timely signals. Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI-powered trading bots from a universe of hundreds that trade thousands of tickers across equities, ETFs, and forex. Only bots demonstrating consistent, verifiable performance metrics earn placement in this section, giving users visibility into strategies that range from short-term momentum plays to longer-duration swing and trend-following approaches. Exploring this resource has helped me evaluate algorithmically driven approaches that complement traditional fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for ISRG turns positive, indicating new upward trend
ISRG saw its Momentum Indicator move above the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ISRG's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ISRG just turned positive on August 03, 2026. Looking at past instances where ISRG's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
ISRG moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in of 325 cases, the price rose further within the following month. The odds of a continued upward trend are .
ISRG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 272 cases where ISRG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ISRG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.800) is normal, around the industry mean (5.089). P/E Ratio (46.017) is within average values for comparable stocks, (138.307). Projected Growth (PEG Ratio) (1.968) is also within normal values, averaging (3.484). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (13.089) is also within normal values, averaging (66.890).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther
Advertisement